aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
UCB is a global biopharmaceutical company headquartered in Brussels, Belgium. The company focuses on developing innovative solutions for people living with neurological and autoimmune conditions. UCB's mission is to create valuable treatments that improve the lives of patients, driven by the belief that everyone deserves to live their best life possible.
As a leader in the biopharmaceutical industry, UCB specializes in the treatment of central nervous system disorders and inflammatory diseases. The company works closely with patients, caregivers, and healthcare professionals to forge strong connections and deliver impactful solutions. UCB's approach combines scientific expertise with a patient-centric focus, aiming to make meaningful improvements in the lives of those affected by these conditions.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Pharmaceuticals
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was UCB founded?
UCB was founded in 1928.
Where is UCB’s headquarters located?
UCB’s headquarters is located in BE.
When was UCB’s last funding round?
UCB’s most recent funding round was for $94.5M (USD) in May 2022.
How many employees does UCB have?
UCB has 7600 employees as of Feb 6, 2024.
How much has UCB raised to-date?
As of July 05, 2023, UCB has raised a total of $195.3M (USD) since May 24, 2022.
Add Comparison
Total Raised to Date
$195.3M
USD
Last Update May 24, 2022
Last Deal Details
$94.5M
USD
May 24, 2022
Post Ipo Equity
Total Employees Over Time
7600
As of Feb 2024
UCB Address
Belgium
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts